(Q28066498)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

review article

1 reference

title

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Frank-Peter Theil

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

author name string

Alison Smith

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Hugh Manoli

2

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Stacey Jaw

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Kimberley Frutoz

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Alan L Epstein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

language of work or name

1 reference

8 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

Journal of Immunology Research

22 March 2020

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

volume

2016

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

page(s)

2342187

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

22 March 2020

copyright license

start time

1 January 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Targeting FcRn for the modulation of antibody dynamics

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

The lung as a route for systemic delivery of therapeutic proteins and peptides

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcgammaRIIb2

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity of protein therapeutics

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

CD4+ T-cell epitope prediction using antigen processing constraints

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Software tools for simultaneous data visualization and T cell epitopes and disorder prediction in proteins

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity of long-lasting recombinant factor VIII products

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Large-scale production of human pluripotent stem cell derived cardiomyocytes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Engineering less immunogenic and antigenic FVIII proteins

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Cancer Neoantigens and Applications for Immunotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Design and optimization of peptide nanoparticles

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Influence of molecular size on tissue distribution of antibody fragments

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

United States Food and Drug Administration Regulation of Gene and Cell Therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Current status of pig lung xenotransplantation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Rodents as pre-clinical models for predicting vaccine performance in humans.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity and other problems associated with the use of biopharmaceuticals

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Biologics: an update and challenge of their pharmacokinetics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Clinical development success rates for investigational drugs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity of mAbs in non-human primates during nonclinical safety assessment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity of therapeutic proteins: influence of aggregation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Preclinical models used for immunogenicity prediction of therapeutic proteins

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity of therapeutic proteins: the use of animal models

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Impact of product-related factors on immunogenicity of biotherapeutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

T cell epitope: friend or foe? Immunogenicity of biologics in context

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Glycosylation as a strategy to improve antibody-based therapeutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Pure red cell aplasia induced by erythropoiesis-stimulating agents.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Effects of protein aggregates: an immunologic perspective

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity of recombinant human proteins: causes and consequences

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity of therapeutic proteins: clinical implications and future prospects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Population pharmacokinetics: theory and practice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Interferon-Beta: Neutralizing Antibodies, Binding Antibodies, Pharmacokinetics and Pharmacodynamics, and Clinical Outcomes

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies

2 June 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F2342187

Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F2342187

HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F2342187

Expeditious screening of candidate proteins for microbial vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F2342187

In silico epitope analysis of unique and membrane associated proteins from Mycobacterium avium subsp. paratuberculosis for immunogenicity and vaccine evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F2342187

Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F2342187

Subcutaneous absorption of biotherapeutics: knowns and unknowns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F2342187

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F2342187

Inverse relationship of protein concentration and aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F2342187

The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2016%2F2342187

Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4992793

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

27 November 2018

1 reference

12 December 2020

Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease

1 reference

12 December 2020

"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics

1 reference

12 December 2020

1 reference

12 December 2020

Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms

1 reference

12 December 2020

Clinical immunotoxicity of therapeutic proteins

1 reference

12 December 2020

Drug-induced autoimmunity

1 reference

12 December 2020

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

1 reference

12 December 2020

Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment

1 reference

12 December 2020

A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies

1 reference

12 December 2020

[Review on requirements of drug allergy or pseudoallergic reactions in pre-clinical evaluation]

1 reference

12 December 2020

Adaptive Clinical Trials: Overview of Phase III Designs and Challenges

1 reference

12 December 2020

Severe anaphylaxis with recombinant interferon beta

1 reference

12 December 2020

Identifiers

DOI

10.1155/2016/2342187

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27579329%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

PubMed publication ID

27579329

2 references